The TRAIL pathway agonist ONC212 provides an orally bioavailable drug for treating severe esophagitis caused by radiation therapy commonly used in the treatment of lung, breast, esophageal, oral, or head and neck cancers. This evidence concerns the gene TNFSF10 and head and neck cancer.